Strategies to Accelerate the Development of Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges for project teams. In our latest webinar, experts discuss methodologies for evaluating ADC efficacy, resistance, and immunogenicity that address both antibody-specific and payload-specific mechanisms through various multi-dimensional assays.
This webinar offers a comprehensive perspective on strategies and approaches that are crucial for accelerating research focused on antibody-drug conjugates.
Related Content
Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...
VIEW RESOURCEAntibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where...
VIEW RESOURCE